The United States will give up intellectual property patents for the new crown vaccine. The impact will be beneficial to increasing the global production capacity of the new crown vaccine, but at the same time it will have a negative impact on companies developing vaccines, which will in turn affect their stock prices. 1: The United States will give up the intellectual property patent on the new crown vaccine
The Biden administration of the United States announced that the United States will give up the intellectual property patent on the new crown vaccine, and stated that the new crown epidemic is a global public health crisis that requires extraordinary measures. The U.S. government is well aware of the necessity of intellectual property rights, but in order to end this epidemic, safe and effective vaccines should be popularized as soon as possible. The U.S. government will also continue to strengthen cooperation with the private sector and all possible partners to expand the manufacturing and distribution of vaccines, as well as work to increase the raw materials needed to produce these vaccines. After the announcement of this U.S. decision, it immediately aroused widespread discussion and controversy around the world. Supporters believed that this would increase the production capacity of the global COVID-19 vaccine and would be of great significance to the global fight against the epidemic; while opponents believed that giving up intellectual property patents would It will seriously affect the economic returns due to vaccine development companies, and their market share will also shrink, which will in turn affect the stock prices of these companies. 2: The impact of the United States giving up its patent on the COVID-19 vaccine
The United States announced that it will give up its intellectual property patent on the COVID-19 vaccine, which has had both positive and negative impacts. The positive impact is that there are only a few countries in the world that can develop and produce COVID-19 vaccines. In the face of more than 200 countries and more than 7.5 billion people in the world, the COVID-19 vaccine production capacity of these countries is far from satisfactory. The United States has given up on COVID-19 vaccines. After intellectual property patents are issued, more pharmaceutical companies can join the ranks of producing vaccines, which can increase the production capacity of the new coronavirus vaccine to a certain extent and allow more people around the world to receive the new coronavirus vaccine, which is important for the global fight against the new coronavirus epidemic. It has a positive effect. The negative impact is that after the United States abandons the intellectual property patent for the new coronavirus vaccine, companies that originally developed the new coronavirus vaccine will face more competitors. These companies will not be able to charge considerable patent licensing fees, and their market share will also be affected, thereby reducing the The market's expected earnings for these companies directly affect their stock prices. Moreover, when more companies join the production of COVID-19 vaccines, they may produce low-quality COVID-19 vaccines in order to seize the market. At the same time, the original vaccine manufacturers do not have enough funds and energy to develop new vaccines. These will It will bring certain negative effects to the global new crown vaccine industry. Three: Evaluation of the event
Although the United States will give up the intellectual property patent of the new crown vaccine, the difficulty in producing the new crown vaccine lies in the raw materials and production process. Only a small number of pharmaceutical companies with certain qualifications and capabilities can meet the requirements of the new crown vaccine. Due to the production requirements of the vaccine, the shortage of the new crown vaccine cannot be effectively solved in a short period of time. Regarding the intellectual property patents of the new coronavirus vaccine, because the new coronavirus epidemic is the common enemy faced by all mankind, the new crown vaccine has surpassed the value positioning of ordinary products. At this special moment, the new crown vaccine has become the decisive factor in whether mankind can defeat it as soon as possible. Key to COVID-19. It is recommended that before the global COVID-19 epidemic is effectively controlled, the intellectual property patents of the COVID-19 vaccine should be set to a free period. After the global COVID-19 epidemic is effectively controlled, these original vaccine development companies can resume the COVID-19 vaccine knowledge product patents, which can protect The economic returns that companies deserve will also prevent shoddy COVID-19 vaccines from appearing on the market.